๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
DaVita Inc. (DVA)
NYSE: DVA ยท Real-Time Price ยท USD
162.19
+5.85 (3.74%)
Nov 20, 2026, 3:00 PM EST - Market open

DaVita Earnings Call Transcripts

Fiscal Year 2026

  • Q3 volume missed expectations due to hospitalization-related missed treatments, while census was slightly better than expected; new dialyzers are rolling out to most eligible patients in November. For Q4, calendar headwinds and rising RPT QoQ shape the outlook; IKC and international opportunities remain in focus.

  • International operations are on plan and IKC is expected to contribute ~2% to 2026 operating income growth, while U.S. dialysis faces cost and payer-mix pressure. For 2027, pharmaceutical savings and stronger volume are expected to help offset reimbursement headwinds.

  • Q3 adjusted operating income was $561 million and adjusted EPS was $3.82. IKC raised its FY2026 outlook, while higher technology costs and ACA-related mix pressure temper results; expanded HD rollout begins in November.

  • Second quarter results met expectations with strong volume growth from improved mortality, offset by lower revenue per treatment due to commercial mix and phosphate binder changes. Guidance for 2026 is reaffirmed, with continued investment in clinical innovation and capital allocation discipline.

  • Volume guidance was raised due to competitor clinic closures and improved mortality, with most benefits expected by mid-year. OI growth is supported by international and value-based care, while AI and clinical innovations are being pursued for future efficiency and patient outcomes.

  • First quarter results exceeded expectations, driven by higher treatment volume, improved productivity, and technology investments. Guidance for adjusted operating income and EPS was raised, with additional volume growth expected from competitor clinic closures.

  • 2026 OI growth is projected above the low end of long-term targets, driven by U.S. dialysis, international, and IKC segments. Margin maintenance, cost controls, and IT investments are key, while APTC expiration and clinical programs will shape future mix and volume. Double-digit EPS growth and disciplined capital deployment remain priorities.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019